Asthma News - November 9, 2026
Current asthma research, announcements and opportunities, collected and distributed by Michigan Department of Health & Human Services (MDHHS) Asthma Program Staff. Sign up to receive weekly-ish news emails at MDHHS-Asthma@michigan.gov.
Check out the most recent MDHHS asthma social media messages and share them with your networks.
Allergy & Asthma Network’s Ask the Allergist: Smoking, Vaping, Incense and Asthma
Exposure to secondhand smoke or vaping poses health risks for everyone, but people with asthma are at high risk for symptoms. It can inflame airways and weaken lung function. Learn from allergist Juanita Mora, MD, about the dangers of cigarette smoke, vaping, and exposure to incense and burning candles.
American Journal of Managed Care Video: Biologic Value in Asthma: Oral Steroid Toxicity and Prior Authorization
Expert physicians discuss how biologics can offset their acquisition cost by preventing exacerbations and cumulative steroid toxicity, yet billing structures and prior authorization continue to delay patients who need treatment.
Asthma & Allergy Foundation of America: Health Insurance 101: Open Enrollment
Each year, usually in the fall, you have the chance to change or sign up for health insurance coverage. Learn what you need to know to enroll in a plan, whether you are getting insured for the first time or are switching plans. Health Insurance Marketplace Guide for Asthma and Allergies for 2027
Clinical Evaluation of Allergen Immunotherapy (AIT) for Allergic Asthma
AIT targets the underlying immune dysregulation driving allergic asthma. This narrative review found that AIT represents a uniquely positioned, disease-modifying strategy in the management of allergic asthma, with potential benefits spanning symptom control, prevention of disease onset and progression, and long-term benefits persisting after treatment discontinuation.
Choosing and switching biologics for patients with severe asthma – real-life data from the German Asthma Net
Phenotyping patients with severe asthma determines the initial choice of biologic therapy in real-world practice. Choice and switch of biologic have evolved over time influenced by availability of different drugs.
Adherence to Inhaled Corticosteroids (ICS) and Inflammatory Phenotypes in Asthma
In patients with asthma, adherence to ICS did not differ significantly across inflammatory phenotypes, although patients with T2-low asthma tended to show lower adherence. Among males, adherence varied by phenotype, with T2-high and possible T2-high asthma associated with lower odds of good adherence.